Cynapsus Therapeutics Company Profile (OTCMKTS:CYNAF)

About Cynapsus Therapeutics (OTCMKTS:CYNAF)

Cynapsus Therapeutics logoCynapsus Therapeutics Inc is a Canada-based specialty central nervous system (CNS) pharmaceutical company. It develops a sublingual thin film for the potential treatment for on-demand management of debilitating OFF episodes associated with Parkinson's disease (PD). The Company completed a Phase two clinical trial for its product candidate, APL-130277, a sublingual formulation of apomorphine hydrochloride, or apomorphine. Apomorphine is the only molecule approved for acute, intermittent treatment of OFF episodes for advanced PD patients, but is currently only approved as a subcutaneous injection in the United States. APL-130277 is a turning ON medication designed to convert a PD patient from the OFF to the ON state while avoiding the issues associated with subcutaneous delivery of apomorphine. It is designed to convert all types of OFF episodes, including morning OFF episodes. Furthermore, the Company has initiated its pivotal Phase three clinical program for APL-130277.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 52 Week Range: $8.00 - $19.52
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.24
  • P/E Growth: 0
  • Average Volume: 9,127 shs.

Frequently Asked Questions for Cynapsus Therapeutics (OTCMKTS:CYNAF)

What is Cynapsus Therapeutics' stock symbol?

Cynapsus Therapeutics trades on the OTCMKTS under the ticker symbol "CYNAF."

How were Cynapsus Therapeutics' earnings last quarter?

Cynapsus Therapeutics Inc (OTCMKTS:CYNAF) announced its earnings results on Wednesday, November, 12th. The company reported ($0.02) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.03) by $0.01. View Cynapsus Therapeutics' Earnings History.

Who are some of Cynapsus Therapeutics' key competitors?

How do I buy Cynapsus Therapeutics stock?

Shares of Cynapsus Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cynapsus Therapeutics' stock price today?

One share of Cynapsus Therapeutics stock can currently be purchased for approximately $0.97.

MarketBeat Community Rating for Cynapsus Therapeutics (OTCMKTS CYNAF)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  16 (Vote Outperform)
Underperform Votes:  10 (Vote Underperform)
Total Votes:  26
MarketBeat's community ratings are surveys of what our community members think about Cynapsus Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cynapsus Therapeutics (OTCMKTS:CYNAF) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Cynapsus Therapeutics (OTCMKTS:CYNAF)
No equities research coverage for this company has been tracked by


Earnings History for Cynapsus Therapeutics (OTCMKTS:CYNAF)
Earnings by Quarter for Cynapsus Therapeutics (OTCMKTS:CYNAF)
Earnings History by Quarter for Cynapsus Therapeutics (OTCMKTS CYNAF)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/12/2014($0.03)($0.02)ViewN/AView Earnings Details
8/14/2014($0.03)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Cynapsus Therapeutics (OTCMKTS:CYNAF)
Current Year EPS Consensus Estimate: $-3.15 EPS
Next Year EPS Consensus Estimate: $-4.00 EPS


Dividend History for Cynapsus Therapeutics (OTCMKTS:CYNAF)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Cynapsus Therapeutics (OTCMKTS:CYNAF)
No insider trades for this company have been tracked by


Headline Trends for Cynapsus Therapeutics (OTCMKTS:CYNAF)
Latest Headlines for Cynapsus Therapeutics (OTCMKTS:CYNAF)
DateHeadline logo15 Stocks Moving In Thursday's Pre-Market Session - September 1 at 9:38 AM



Cynapsus Therapeutics (CYNAF) Chart for Wednesday, September, 20, 2017

This page was last updated on 9/20/2017 by Staff